More recent experiments, involving the administration of a part CBD part THC solution, have yielded results that contradict the first supposition. At present, on the evidence that cannabidiol reduces some of the psychoactive effects of tetrahydrocannabinol (acting as a de facto antidepressant), scientists argue that cannabidiol has a holistic but indirect influence on all cannabinoid receptors in the endocannabinoid system. The main consequence of this impact seems to be an increase in the production of endocannabinoids. This is now the prevailing idea that accounts for the mountains of empirical evidence of how the benefits of cannabidiol are expressed at the cellular level.
Cachexia is a disorder involving dangerous weight loss brought on by diseases as diverse as AIDS, cancer or Alzheimer’s. A 2011 German study involving more than 100 people proved that patients on the placebo lost about 80 percent more weight weekly than those administered a cannabinoid cocktail. This, along with the mood-elevating properties of cannabidiol implies future applications for the treatment of widespread eating disorders such as anorexia nervosa.
As is the case with any plant that constitutes a crop, cannabis plants have been selectively bred over the years to bolster one or another desired characteristic. This means that some plants provide a more potent psychotropic effect, others possess more prominent seeds (used in the production of cooking oil traditionally), while others may make for sturdier textile fibers.